spacer
spacer

PDBsum entry 8ayh

Go to PDB code: 
protein ligands metals Protein-protein interface(s) links
Immune system PDB id
8ayh

 

 

 

 

Loading ...

 
JSmol PyMol  
Contents
Protein chains
648 a.a.
815 a.a.
951 a.a.
Ligands
H1H
Metals
_MG
PDB id:
8ayh
Name: Immune system
Title: Structure of complement c5 in complex with small molecule inhibitor and cvf
Structure: Complement c5 beta chain. Chain: c. Fragment: beta chain, unp residues 1-675. Complement c5 alpha chain. Chain: a. Cobra venom factor. Chain: b. Synonym: cvfk,complement c3 homolog
Source: Homo sapiens. Human. Organism_taxid: 9606. Naja kaouthia. Monocled cobra. Organism_taxid: 8649
Authors: H.Srinivas
Key ref: K.Jendza et al. (2019). A small-molecule inhibitor of C5 complement protein. Nat Chem Biol, 15, 666-668. PubMed id: 31209353 DOI: 10.1038/s41589-019-0303-9
Date:
02-Sep-22     Release date:   21-Dec-22    
Supersedes: 6i2x
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chain
Pfam   ArchSchema ?
P01031  (CO5_HUMAN) -  Complement C5 from Homo sapiens
Seq:
Struc:
 
Seq:
Struc:
 
Seq:
Struc:
 
Seq:
Struc:
1676 a.a.
648 a.a.
Protein chain
Pfam   ArchSchema ?
P01031  (CO5_HUMAN) -  Complement C5 from Homo sapiens
Seq:
Struc:
 
Seq:
Struc:
 
Seq:
Struc:
 
Seq:
Struc:
1676 a.a.
815 a.a.
Protein chain
Pfam   ArchSchema ?
Q91132  (VCO3_NAJKA) -  Cobra venom factor from Naja kaouthia
Seq:
Struc:
 
Seq:
Struc:
 
Seq:
Struc:
 
Seq:
Struc:
1642 a.a.
951 a.a.
Key:    PfamA domain  Secondary structure

 

 
DOI no: 10.1038/s41589-019-0303-9 Nat Chem Biol 15:666-668 (2019)
PubMed id: 31209353  
 
 
A small-molecule inhibitor of C5 complement protein.
K.Jendza, M.Kato, M.Salcius, H.Srinivas, A.De Erkenez, A.Nguyen, D.McLaughlin, C.Be, C.Wiesmann, J.Murphy, P.Bolduc, M.Mogi, J.Duca, A.Namil, M.Capparelli, V.Darsigny, E.Meredith, R.Tichkule, L.Ferrara, J.Heyder, F.Liu, P.A.Horton, M.J.Romanowski, M.Schirle, N.Mainolfi, K.Anderson, G.A.Michaud.
 
  ABSTRACT  
 
The complement pathway is an important part of the immune system, and uncontrolled activation is implicated in many diseases. The human complement component 5 protein (C5) is a validated drug target within the complement pathway, as an anti-C5 antibody (Soliris) is an approved therapy for paroxysmal nocturnal hemoglobinuria. Here, we report the identification, optimization and mechanism of action for the first small-molecule inhibitor of C5 complement protein.
 

 

spacer

spacer